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ABSTRACT 
A simple stability-indicating high-performance liquid chromatographic method was developed and validated for the determination of 
Brexpiprazole in tablet dosage forms. Reversed-phase chromatography was performed on Shimadzu Model CBM-20A/20 Alite, using a mixture 
of 0.1% acetic acid and methanol (65:35, v/v) as mobile phase with a flow rate of 0.9 mL/min.  Detection was carried at 214nm. Linearity was 
observed over the concentration range of 0.1–250 μg/mL (R2 = 0.9999) with regression equation y = 39617.94x + 3300.8. Brexpiprazole was 
subjected to stress conditions (acidic, alkaline, oxidation and thermal degradation) and validated as per ICH guidelines. The validated method 
can be applied to perform long-term and accelerated stability studies of Brexpiprazole formulations.  
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1. INTRODUCTION 
Brexpiprazole (BXP), chemically known as 7-{4-[4-(1-
benzothiophene-4-yl) piperazin-1-yl] butoxy}-1, 2-
dihydroquinoline-2-one is an atypical antipsychotic 
indicated for the treatment of schizophrenia and adjunctive 
treatment of MDD 1. Brexpiprazole (Figure 1) is a partial 
agonist at 5-HT1A and D2 receptors with similar potency, 
and an antagonist at 5-HT2A and adrenergic α1B/2C 
receptors. Compared with aripiprazole, brexpiprazole is 
more potent at 5-HT1A receptors and displays less intrinsic 
activity at D2 receptors 2. 
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Figure 1: Chemical structure of Brexpiprazole 
Literature survey revealed that Brexpiprazole was 
determined by UV-Visible spectroscopy 3 and HPLC 4, 5. In the 
present study, the authors have proposed four simple 
validated spectrophotometric methods for the determination 
of Brexpiprazole in pharmaceutical dosage forms. At present, 
the authors have developed stability indicating RP-HPLC 
method for the determination of Brexpiprazole in presence 
of its degradation products. 
2. MATERIALS AND METHODS 
2.1. Chemicals and reagents:  
HPLC grade Methanol (Merck), glacial acetic acid (Merck), 
sodium acetate trihydrate (Merck), Hydrochloric acid 
(Rankem), sodium hydroxide (Rankem), Hydrogen peroxide 
(Rankem) was used. Brexpiprazole, obtained as a gift sample 
from MSN Life Sciences Pvt. Ltd., (India), was used. 
Brexpiprazole is available with brand name Rexulti (0.5 mg 
and 1mg of the drug per tablet; Otsuka America 
Pharmaceuticals Inc.) were purchased from the local market.  
2.2. Instrumentation and conditions:  
Chromatographic separation was achieved by using a 
Shimadzu Mode.000l CBM-20A/20 Alite HPLC system, 
equipped with SPD M20A prominence photodiode array 
detector with Phenomenex C18 (250 mm × 4.6 mm i.d., 5 µm 
particle size) column kept up at 25 ºC.  
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2.3. Preparation of stock solution: 
Brexpiprazole stock solution (400 μg/mL) was prepared by 
weighing accurately 10 mg of BXP in a 25 mL volumetric 
flask with methanol. Working standard solutions were 
prepared on daily basis from the stock solution with 
methanol. 
2.4. Preparation of 0.1% Acetic acid: 
1mL of acetic acid was dissolved in HPLC grade water in a 
1000 mL volumetric flask (pH 3.90). 
Isocratic elution was performed using 0.1% acetic acid and 
methanol (65:35, v/v). The overall run time was 10 min. and 
the flow rate was 0.9 mL/min. 20 µL of sample was infused 
into the HPLC system.  
3. METHOD VALIDATION  
The method was validated for system suitability, linearity, 
and limit of quantitation (LOQ), limit of detection (LOD), 
precision, accuracy, selectivity, and robustness.  
3.1. Linearity: 
Linearity test solutions for the assay method were set up 
from a stock solution at various concentration levels (0.1– 
250 μg/mL) of the assay analyte concentration and 20 µL of 
each solution was infused into the HPLC system and the 
obtained peak area region from the chromatogram was 
noted. The calibration curve was plotted by taking the 
concentration on the x-axis and the relating peak area on the 
y-axis. The data were treated with linear regression analysis 
method. The limit of quantification and limit of detection 
depended on the standard deviation of the response and the 
slope of the constructed calibration curve (n=3), as 
described in ICH guidelines Q2 (R1) 6.  
3.2. Precision and accuracy: 
The intra-day precision of the assay method was evaluated 
by carrying out 9 independent assays of a test sample of BXP 
at three concentration levels (10, 20 and 50 μg mL) (n=3) 
against a qualified reference standard. The %RSD of three 
acquired assay values at three diverse concentration levels 
was determined. The inter-day precision study was 
performed on three different days i.e. day-I, day-II and day-
III at three different concentration levels (10, 20 and 50 
μg/mL) and each value is the average of three 
determinations (n=3). The % RSD of the three obtained 
assay values on three different days was calculated. The 
accuracy of the assay method was assessed in triplicate at 
three concentration levels (50, 100 and 150%), and the 
percentage recoveries were determined. Standard addition 
and recovery experiments were conducted to determine the 
accuracy of the method for the quantification of BXP in the 
drug product. The study was carried out in triplicate at 50, 
100 and 150 μg/mL. The percentage of recovery in each case 
was calculated. 
3.3. Robustness: 
The robustness of the assay method was established by 
providing small changes in the HPLC conditions which 
included wavelength (209 and 219 nm), the percentage of 
methanol in the mobile phase (33 and 37%) and flow rate 
(0.8 and 1.0 mL/min). Robustness of the method was studied 
utilizing six replicates at a concentration level of 100 μg/mL 
of BXP. 
3.4. Assay of marketed formulations (Tablets): 
Solutions were also prepared by extracting the marketed 
formulations (Tablets) with the methanol and filtered. The 
filtrate so obtained was diluted as per the requirement and 
20 µL solution of each of the marketed formulations 
(REXULTI®) was injected into the HPLC system and from the 
calibration curve, the percentage recovery was calculated.   
3.5. Forced degradation studies:  
Forced degradation studies were performed to assess the 
stability indicating properties and specificity of the method. 
All solutions for stress studies were prepared at an initial 
concentration of 400µg/mL of BXP and refluxed for 2 hours 
at 60 ºC and then diluted with methanol.   
400µg/mL of BXP solution was exposed to acidic 
degradation with 0.1 M HCl for 2 hours at 60 ºC the stressed 
sample was cooled, neutralized and diluted with methanol. 
Similarly, stress studies were conducted in alkaline 
conditions with 0.1 M NaOH at 60 ºC for 2 hours and 
neutralized after cooling with proper dilution with methanol.  
Oxidative stress studies were performed using 30 % H2O2 
and thermal stress studies were conducted in the thermostat 
at 60 ºC for 2 hours. 20 µL solution of each of the solutions 
under forced degradation studies were infused into the HPLC 
system and the chromatograms were recorded from which 
the percentage recovery and also the degradants were 
studied. 
4. RESULTS AND DISCUSSION  
Initially, the stressed samples were analyzed using a mixture 
of 0.1% acetic acid and methanol (50:50, v/v). with a flow 
rate of 0.7 mL/min in which the resolution and peak 
symmetry was not satisfactory. The flow rate was changed to 
0.9 mL/min and the drug sample was injected into the loop 
where a sharp peak was eluted at 3.545 minutes with tailing. 
Finally, the mobile phase composition was modified as 
65:35, v/v and the drug peak eluted were sharp and 
symmetrical (UV detection at 214 nm) with retention time 
less than 5 minutes (2.17 ± 0.03 min). Brexpiprazole shows 
linearity over a concentration range of 0.1–250 μg/mL 
(Table 1) with % RSD 0. 24-0.65. The linear regression 
equation was found to be y = 39617.9x +3300.8 (R2 = 
0.9999). The LOQ was found to be 0.0614μg/mL and the LOD 
was found to be 0.0203μg/mL. The % RSD range was 
obtained as 0.24-0.45 and 0.14-0.61 for intra-day and inter-
day precision studies respectively (Table 2). 99.70-100.14 % 
of recovery was observed in the accuracy studies with % 
RSD 0.42-0.62 (<2.0 %) (Table 2). 
Table 1: Linearity of Brexpiprazole 
Table 1: Linearity of Brexpiprazole 
Conc. Mean peak area RSD 
0.1 3475±15.6375 0.45 
0.5 19654±125.7856 0.64 
1 39775±135.235 0.34 
10 401587±963.8088 0.24 
20 789657±2526.902 0.32 
50 2006445±9029.003 0.45 
100 3947575±24474.97 0.62 
150 5998743±25194.72 0.42 
200 7854287±29060.86 0.37 
250 9937192±64591.75 0.65 
*Mean of three replicates
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Table 2: Precision and accuracy studies of Brexpiprazole 
Conc. 
(µg/mL) 
Intra-day precision Inter-day precision 
* Mean peak area ± SD (% RSD) * Mean peak area ± SD (% RSD) 
10 401587±963.8088 (0.24) 401323± 784.36 (0.19) 
20 789657±2526.902 (0.32) 789489± 1078.23  (0.14) 
50 2006445±9029.003 (0.45) 2005789± 12223.17 (0.61) 
Accuracy 
Spiked conc. 
(µg/mL) 
Total conc. 
(µg/mL) 
* Mean peak area ± SD (% RSD) 
Drug Found 
(µg/mL) 
% Recovery 
25 (50 %) 50 2006369±9185.007 (0.46) 49.85 99.70 
75 (100 %) 100 3947489±24378.47 (0.62) 99.84 99.84 
125(150 %) 150 5998813±25384.52 (0.42) 150.21 100.14 
*Mean of three replicates 
The robustness of an analytical procedure refers to its 
capacity to stay unaffected by small or deliberate variations 
in method parameters and gives an indication of its 
reliability for routine analysis. The robustness of the method 
was evaluated by testing a similar sample under various 
analytical conditions deliberately changing from the first 
condition. The outcomes obtained (Table 3) from the assay 
of the test solutions were not influenced by varying the 
conditions and were as per the results for unique conditions. 
The % RSD value of assay for a similar sample under original 
conditions and robustness conditions was under 2.0% (0.29-
0.64) showing that the developed method was robust. 
The representative chromatogram, 3D Curve and Peak Purity 
Curve of Brexpiprazole were shown in Figure 2A, 3A, 4A. The 
proposed method was applied to the marketed formulations 
(REXULTI®) and the percentage recovery was 98.41-100.14 
(Table 4) without the interference from the excipients used 
in these tablets (Figure 2B-2C, 3B-3C& 4B-4C). 
 
 
(a) 
 
(b) 
 
(c) 
Figure 2: Typical chromatograms of Brexpiprazole (a) Standard Drug (10 μg ml-1) (b) Formulation 1: REXULTI® (Label claim: 
0.5 mg) and (c) Formulation 2: REXULTI® (Label claim: 1.0 mg). 
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(a)                                                                                               (b) 
 
 
(c) 
Figure 3: Typical 3D curves of Brexpiprazole (a) Standard Drug (10 μg ml-1) (b) Formulation 1: REXULTI® (Label claim: 0.5 mg) 
and (c) Formulation 2: REXULTI® (Label claim: 1.0 mg). 
 
(a)                                                                         (b) 
 
(c) 
Figure 4: Peak Purity curves of Brexpiprazole (a) Standard Drug (10 μg ml-1) (b) Formulation 1: REXULTI® (Label claim: 0.5 
mg) and (c) Formulation 2: REXULTI® (Label claim: 1.0 mg).  
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Table 3: Robustness study of Brexpiprazole 
 
Parameter Condition *Mean peak area 
*Mean peak area ± SD 
(% RSD) 
*Assay 
(%) 
Flow rate 
(± 0.9 mL/min) 
0.8 3941418 
3961253.33 ± 23718.48 
(0.59) 
99.84 0.9 3954816 
1.0 3987526 
Detection wavelength 
(± 5 nm) 
 
209 3942422 
3936972.33 ± 23221.16 
(0.59) 
98.91 214 3956984 
219 3911511 
Mobile phase composition 
(0.1% acetic acid: methanol) 
(± 2 %, v/v) 
63:37 3951875 
3959336.00 ± 25332.39 
(0.64) 
100.01 65:35 3938572 
67:33 3987561 
pH (± 0.1 unit) 
3.8 3965871 
3974062.33 ± 11779.59 
(0.29) 
99.71 3.9 3987562 
4.0 3968754 
*Mean of three replicates 
 
Table 4: Analysis of Brexpiprazole commercial formulation (Tablets) 
Sample No. Formulation Labeled claim (mg) *Amount found   (mg) *Recovery (%) 
1 Brand I 0.5 0.496 99.20 
1 Brand II 1.0 0.994 99.40 
*Mean of three replicates 
 
The stability indicating the capability of the method was 
established from the separation of BXP peak from the 
degraded samples. The degradation of BXP was found to be 
very similar for both the tablets and standard. Typical 
Chromatogram 3D curves and peak purity curves 
chromatograms obtained following the assay of stressed 
samples is shown in Figure 5A-5E, 6A-6E, and 7A-7E 
respectively. A slight decomposition was seen on exposure of 
BXP drug solution to acidic (0.14 %), alkaline (0.18 %), 
oxidative (8.64 %) and thermal (0.86 %) conditions. The 
degradants were observed at 1.585, 1.757 and 1.986 min in 
oxidation degradations without interfering with the 
Brexpiprazole peak indicating that the method is specific. 
The percentage of drug degradation was less than 10% in all 
stressed conditions indicating that Brexpiprazole is very 
much resistant (Table 5). 
The present stability-indicating method for the 
determination of BXP in pharmaceutical formulations is 
specific because the drug peak was well separated even in 
the presence of degradation products. Also, Brexpiprazole is 
more resistant towards all degradations and the overall data 
demonstrated that the excipients and the degradation 
products did not interfere with the BXP peak. The system 
suitability parameters for the BXP peak shows that the 
theoretical plates were more than 2000 and the tailing factor 
was less than 2 (or <1.5-2.0) (Table 5). 
 
 
 
 
 
 
 
 
 
 
Goutham Kumar et al                                                                                      Journal of Drug Delivery & Therapeutics. 2019; 9(2-s):214-222 
ISSN: 2250-1177                                                                                  [219]                                                                                 CODEN (USA): JDDTAO 
 
(a) 
 
(b) 
 
(c) 
 
(d) 
 
(e) 
Figure 5: Typical Chromatograms of Brexpiprazole (10μg/ml) on (a) Acidic degradation, (b) Alkaline degradation, (c) Oxidative 
degradation and (d) Thermal degradation and (e) Photolytic degradation. 
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(e) 
Figure 6: Typical 3D Curves of Brexpiprazole (10μg/ml) on (a) Acidic degradation, (b) Alkaline degradation, (c) Oxidative 
degradation and (d) Thermal degradation and (e) Photolytic degradation. 
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(e) 
Figure 7: Peak Purity Curves of Brexpiprazole (10μg/ml) on (a) Acidic degradation, (b) Alkaline degradation, (c) Oxidative 
degradation and (d) Thermal degradation and (e) Photolytic degradation. 
 
Table 5: Forced degradation studies of Brexpiprazole 
Stress Conditions 
*Mean peak 
area 
*Drug 
recovered 
(%) 
*Drug 
decomposed 
(%) 
Theoretical 
plates 
Tailing 
factor 
Standard drug (Untreated) 3947575 100 - 7548.15 1.254 
Acidic degradation 1 ml 0.1N 
HCl, 80°C, 30 mins 
3942048 99.86 0.14 7365.19 1.287 
Alkaline degradation 0.1 ml 
0.1N NaOH, 80°C, 30 mins 
3940469 99.82 0.18 7247.36 1.282 
Oxidative degradation 1 ml 3% 
H2O2, 80°C, 30 mins 
3606504 91.36 8.64 7258.36 1.267 
Thermal degradation 
105°C, 30 mins 
3913626 99.14 0.86 7247.96 1.258 
*Mean of three replicates 
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5. CONCLUSION 
The proposed stability-indicating HPLC method was 
validated as per ICH guidelines and applied for the 
determination of Brexpiprazole in pharmaceutical dosage 
forms and can be successfully applied to perform long-term 
and accelerated stability studies of Brexpiprazole 
formulations.  
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